Nthabeleng Ranchobe

TL;DR: It is shown, in two HIV-1–infected individuals who developed BCN antibodies targeting the glycan at Asn332 on the gp120 envelope, that this glycan was absent on the initial infecting virus, which highlights the dynamic interplay between early antibodies and viral escape in driving the evolution of conserved BCN antibody epitopes.

TL;DR: The data suggest the development of a very limited number of neutralizing antibody specificities during the early stages of HIV-1 subtype C infection, with temporal fluctuations in specificities as escape occurs.

TL;DR: It is shown that cross-reactive anti-V3 antibodies developed within 3 to 12 weeks in six individuals but did not mediate autologous neutralization, and that epitopes in this region are major targets of the early autOLOGous neutralizing response in HIV-1 subtype C infection.

TL;DR: Comparison of the CAP256 epitope with that of the PG9/PG16 monoclonal antibodies suggested that these epitopes overlapped, adding to the mounting evidence that this may represent a common neutralization target that should be further investigated as a potential vaccine candidate.